Return to Listing

1 result(s) for

PI Name Protocol # Title
Craig Okada STUDY00019561 An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K δ/γ dual inhibitor, given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080